NEW YORK (GenomeWeb) – Qiagen said today that its QiaStat-Dx syndromic testing system and multiplex respiratory pathogen panel have received 510(k) clearance from the US Food and Drug Administration.
With the clearance, Qiagen is commercially launching the products in the US, the company said.